Symbol Lookup

News Article

News Headlines

Keyword
Go

Today

Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA(R) (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
4 minutes ago by Business Wire
Companies Mentioned: MRK

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA(R) (pembrolizumab), the company's anti-PD-1 therapy, in naive and previous...

Pembrolizumab, Merck's Investigational anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab, an Anti-CTLA-4 Therapy, in a Phase 3 Study of Patients with Advanced Melanoma
4 minutes ago by CNW Group
Companies Mentioned: MRK

Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal ...

Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pembrolizumab Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
4 minutes ago by CNW Group
Companies Mentioned: MRK

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating pembrolizumab, the company's investigational anti-PD-1 therapy, in naïve and previously-treated patient...

KEYTRUDA(R) (pembrolizumab), Merck's Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
4 minutes ago by Business Wire
Companies Mentioned: MRK

--Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine

--Merck Plans to Submit sBLA for First-Line Indication in Advanced Melanoma in Mid-2015

Merck's Keytruda shrinks lung cancer tumors, FDA approval sought
4 minutes ago by Thomson Reuters
Companies Mentioned: MRK, BMY

By Deena Beasley

April 19 (Reuters) - Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half o...

Euro working group to meet Wednesday, deal still sought - Greek official
10 minutes ago by Thomson Reuters

ATHENS, April 19 (Reuters) - Euro zone deputy finance ministers will meet midweek ahead of a Eurogroup finance ministers' gathering two days later, a ...

WRAPUP-Oil slide slashes Q1 profit, not investment plans at Saudi's SABIC
32 minutes ago by Thomson Reuters

* Q1 profit slides 39 pct y/y; revenues off 28 pct

* But beats analysts' forecasts by substantial margin

* Postponing non-vital spending but anticipatin...

Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA(R) (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
34 minutes ago by Business Wire
Companies Mentioned: MRK

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for KEYTRUDA(R)...

RPT-Republican hopefuls target middle-class insecurity as economy improves
34 minutes ago by Thomson Reuters

(Repeats story with no change to text)

By James Oliphant and Andy Sullivan

NASHUA, April 19 (Reuters) - Facing a recovering economy and a tumbling joble...

Merck files for FDA approval of Keytruda in lung cancer
34 minutes ago by Thomson Reuters
Companies Mentioned: MRK, A, BMY

By Deena Beasley

April 19 (Reuters) - Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its dr...